Boyoung Wee Trent

Boyoung Wee Trent, Ph.D., currently serves as Senior Director of Global Commercial Strategy for Immunology at Regeneron since May 2022, with additional responsibilities in Global Marketing for Itepekimab. Previous roles include Senior Director of Commercial Strategy & New Product Planning at BioXcel Therapeutics, Inc. from 2020 to 2022, and Director of Business Planning & Commercial Operations at DBV Technologies from 2018 to 2020. Boyoung Trent also worked as a Management Consultant at Navigant Consulting, Campbell Alliance from 2013 to 2018, and as a Research Fellow at Memorial Sloan Kettering Cancer Center from 2008 to 2013. Education includes a Doctor of Philosophy (Ph.D.) in Pharmacology, Cancer Biology & Genetics from Weill Cornell Medical College / Memorial Sloan-Kettering Cancer Center and a Bachelor's Degree in Biology with a concentration in Pharmacology from Duke University.